FST.L Regulatory News (FST)

29 July 2011

Toumaz Limited

Half year trading update

Toumaz Limited (AIM: TMZ, 'Toumaz', or 'the Group'), a pioneer in low cost, ultra low power wireless communications and broadcast technology, has published a half year trading update for the six months to end of June 2011.

The Group has achieved significant milestones during the first half and traded in line with expectations.

As at 31 June 2011, the Group had a cash balance of £3.3m (£2.9m as at 31 December 2010).

Healthcare

The Sensium disposable digital plaster ('Sensium plaster') received 510(K) approval from the FDA in early July 2011, which will enable product development and preparation for volume production of the Sensium plaster to be finalised during the second half of 2011. A soft launch is planned in US hospitals at the end of 2011 with a formal launch expected in mid 2012.

On 11 July 2011, Toumaz established a new Joint Venture ('JV') with Dr Patrick Soon-Shiong's company, California Capital Equity LLC ('CCE'), to continue development, commercialisation and distribution of the Sensium plaster in North America and worldwide.

Toumaz's previous Strategic Partner has agreed to license its IP relating to the Sensium plaster to Toumaz, in exchange for a royalty interest in the Sensium plaster. Toumaz will license all relevant IP, owned by itself and by the Strategic Partner, to the new JV.

CCE will fund the JV over the next two years with up to $25m. Toumaz will receive development fees from Toumaz US, 10% royalties on sales of any JV products and benefit from a 20% ownership in the JV. Toumaz retains the rights for the use of the Sensium technology for all other non-disposable applications.

In Asia, Quanta Computer has developed prototype non-disposable consumer ECG and activity monitors for Type II diabetics using Toumaz's Sensium solution. These are currently being tested and development is on schedule.

Consumer

Following the launch of the Xenif multimedia (all-in-one DAB, Wi-Fi, baseband and application processor) chip in Q4 2010 and the Telran ultra-low energy wireless radio chip, in Q1 2011, samples have been sold to customers for testing and design-in into products. Telran technology is embedded in the Sensium.

Development of application related software for the Xenif chip is ongoing with potential customers. The Group has established relationships with some leading distribution companies covering the European and US markets. Telran will be sold mainly through distributors.

Sales during the second half of 2011 will depend on the timing and scale of initial volume product orders, with orders depending on customers' launch plans of new products.

Toumaz expects to publish its half year results in mid September.

Enquiries:

About Toumaz - (www.toumaz.com)

Toumaz is pioneering low cost, ultra-low power wireless technologies for a wide range of markets including medical monitoring and internet-connected consumer devices.

Targeting the Healthcare market, Toumaz's licensable smart sensor interface and transceiver platform, Sensium, is a leader in real-time wireless monitoring of the body's vital signs. Sensium has the potential to transform medical monitoring and reduce the cost of healthcare by wirelessly connecting individuals to healthcare providers - simply, affordably and unobtrusively. For healthcare professionals, this creates new opportunities for pro-active monitoring and improved quality of care. For patients, it delivers new opportunities for lifestyle-compatible personalised healthcare.

Toumaz also uses its ultra low power expertise to design devices for wireless connectivity and internet-connected consumer products. Toumaz currently supplies FM/DAB radio chips and complete modules to leaders in the digital radio market, such as PURE.

Toumaz is an AIM listed company (AIM: TMZ) with development centres in Oxford, UK and Taipei City, Taiwan.